Systems Internship

Amgen Inc. is a multinational biotechnology company headquartered in Thousand Oaks, California, that researches, develops, manufactures and commercializes human therapeutics. Founded in 1980, Amgen grew from an early-stage biotechnology firm into one of the world’s largest independent biotechnology corporations. The company’s stated focus is on harnessing advances in molecular biology and human genetics to discover, develop and deliver medicines that address serious illnesses and improve patient outcomes. Amgen’s business model integrates discovery science, translational research, clinical development, large-scale biologics manufacturing and global commercial operations. Core business activities - Research and discovery: Amgen operates discovery and translational research programs that leverage molecular biology, cell biology, protein engineering and human genetics to identify disease mechanisms and therapeutic targets. The company invests in preclinical research and uses both in‑house and collaborative approaches to advance novel candidate molecules into clinical development. - Clinical development and regulatory approval: Amgen conducts phased clinical trials across indications including oncology, hematology, nephrology, cardiovascular disease, bone health and inflammation. It manages global regulatory submissions and post-marketing obligations to secure and maintain approvals in major markets. - Biologic manufacturing: A significant part of Amgen’s operations is dedicated to the large-scale biologics manufacturing required for protein-based therapies. The company designs and operates manufacturing facilities capable of producing monoclonal antibodies, engineered proteins and other complex biologic products, and it maintains quality and supply chain systems to support global distribution. - Commercialization and global marketing: Amgen markets and sells a portfolio of approved medicines worldwide, maintains sales and medical affairs organizations in multiple regions, and supports product access through payer engagement, patient support programs and distribution partners. It also pursues lifecycle management for approved products and strategic collaborations to expand reach. - Business development and partnerships: Amgen routinely engages in partnerships, licensing agreements and acquisitions to supplement its internal pipeline and capabilities. The company invests in external innovation, academic collaborations and corporate acquisitions to access complementary technologies and therapeutic candidates. Main products and therapeutic areas Amgen’s approved portfolio consists largely of biologic medicines—therapeutic proteins and monoclonal antibodies—targeting diseases with high unmet medical need. Historically and presently, the company has commercialized multiple widely used treatments, spanning supportive oncology care, nephrology, inflammation, bone health and cardiovascular disease. Representative products and categories associated with Amgen include: colony-stimulating factors and supportive-care biologics used in oncology settings; erythropoiesis-stimulating agents and related therapies for certain anemia indications; monoclonal antibodies and receptor-targeted biologics for inflammatory and immune-mediated conditions; agents for bone metabolism disorders; and targeted therapies developed for specific oncology and cardiovascular pathways. Amgen has also developed and introduced biosimilar products into select markets. Pipeline and scientific approach Amgen emphasizes a research strategy that integrates human genetics and deep biological understanding to select drug targets with robust evidence linking target biology to disease. The company advances assets through structured clinical development and seeks to build differentiated therapeutic profiles—such as novel mechanisms of action, improved dosing regimens or targeted patient populations. Amgen’s pipeline historically includes candidate programs across oncology, hematology, cardiovascular disease, bone health, nephrology and inflammatory diseases, as well as earlier-stage research in additional therapeutic areas. Manufacturing and operations Amgen operates multi-product biologics manufacturing facilities that produce complex protein therapeutics at commercial scale. The company invests in technologies and process improvements to enhance yield, consistency and scalability of biologic drug production. In addition to its primary research and manufacturing infrastructure, Amgen maintains global commercial capabilities including regional offices, medical affairs teams, regulatory and pharmacovigilance functions, and patient support services to ensure delivery and safe use of its medicines worldwide. Corporate strategy and positioning Amgen positions itself as a science-driven biopharmaceutical company focused on applying advanced biology to create clinically meaningful therapies. The company pursues a dual strategy of advancing internal discovery programs while augmenting its portfolio through acquisitions, licensing and collaborations. Amgen seeks to address high-burden diseases with targeted, biologic-driven medicines and to sustain long-term growth through innovation, lifecycle management of existing products and expansion into new indications and geographic markets. Global presence and impact Amgen has a worldwide commercial presence and supplies therapies to healthcare providers in numerous countries. The company’s operations encompass research sites, manufacturing facilities and commercial affiliates distributed across the Americas, Europe and the Asia-Pacific region. Amgen supports medical education and patient access initiatives and participates in public reporting of clinical trial results and safety data as part of its regulatory and corporate responsibilities. Governance and public reporting As a publicly traded company, Amgen publishes regular financial reports, regulatory filings and corporate responsibility disclosures. The company provides information on clinical development programs, safety data, manufacturing quality systems and supply chain considerations through official channels for investors, healthcare professionals and the public. Overall, Amgen is recognized as a major independent biotechnology company whose core activities span discovery science, biologics manufacturing, clinical development and global commercialization of protein-based therapeutics. The company’s operations and product portfolio emphasize biologic medicines and targeted therapies aimed at improving outcomes in severe and chronic medical conditions.